Meet-URO Score Validation in Real-world Patients with Metastatic Renal Cell Carcinoma Receiving First-line Pembrolizumab Plus axitinib: A Subanalysis of the Prospective ProPAXI Study. jkcvhl. 2025;12(4):7-18. doi:10.15586/jkcvhl.v12i4.403